Distinguished in Febrile Neutropenia

V C. Heijnen-Tjan

Maastricht, LI, NL 
Distinguished in Febrile Neutropenia
Maastricht, LI, NL 
OverviewLocationsClinical Research

Overview

V Heijnen-Tjan practices in Maastricht, Netherlands. Heijnen-Tjan is rated as a Distinguished expert by MediFind in the treatment of Febrile Neutropenia. Their top areas of expertise are Breast Cancer, Febrile Neutropenia, Triple-Negative Breast Cancer, Mastectomy, and Pancreaticoduodenectomy.

Their clinical research consists of co-authoring 232 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 7 articles in the study of Febrile Neutropenia.

Locations

Maastricht, LI, Netherlands
Other Locations
Tilburg, NB 5022GC, Netherlands
Doetinchem, GE, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients with Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients with Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drugs: ddAC-CP-Olaparib, ddAC-mini CTC
Study Phase: Phase 3
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial
Enrollment Status: Terminated
Publish Date: July 19, 2022
Intervention Type: Drug
Study Drugs: Carboplatin, Atezolizumab
Study Phase: Phase 2
View 2 Less Clinical Trials

232 Total Publications

Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study.
Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study.
Journal: Breast (Edinburgh, Scotland)
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Heijnen-Tjan's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile